Bladder symptoms during IVF carry systemic cues that extend beyond the urinary tract

Bladder symptoms during in vitro fertilization (IVF) are often dismissed as an expected adverse event—but they frequently carry diagnostic information that extends well beyond the urinary tract, and integrating bladder health into routine fertility consultations rather than waiting for symptoms to emerge would meaningfully improve patient care, according to Aleece Fosnight, MSPAS, PA-C, the founder of the Fosnight Center for Sexual Health and a medical advisor for Aeroflow Urology.

Fosnight described the pattern recognition that distinguishes expected physiologic responses from concerning escalation. During ovarian stimulation, enlarged ovaries occupy increasing pelvic space and compress the bladder, producing bloating, pelvic fullness, urinary frequency, and abdominal pressure—all common and, in isolation, not alarming. What changes the picture is trajectory.

"When those symptoms start to become progressive rather than stable, that raises concern," she said. Rapid weight gain, increasing abdominal distension, severe pain, shortness of breath, nausea, vomiting, and decreased urine output despite adequate hydration are the signals that elevate concern for ovarian hyperstimulation syndrome. The bladder provides a particularly telling cue: Patients with Ovarian Hyperstimulation Syndrome may report urinary frequency early from pressure, then shift to decreased urine output as the syndrome progresses—a pattern that reflects what is happening systemically.

"The bladder often provides a lot of cues on what's actually happening systemically," Fosnight said.

On the structural question of when and how to address bladder health in the IVF process, Fosnight was direct about where current practice falls short.

"I would love to see bladder health become more of a routine part of every IVF consultation, rather than something that we're discussing only when symptoms develop," she said. Simple screening questions—about baseline urgency, voiding frequency, painful bladder symptoms, incontinence, constipation, pelvic pain, dyspareunia, and prior recurrent urinary tract infections—can be administered by any team member and identify patients who need proactive counseling before stimulation begins.

Pre-existing pelvic floor dysfunction is of particular concern. The IVF process introduces multiple converging stressors—frequent ultrasounds, injections, enlarged ovaries, altered movement patterns, constipation, and anxiety—all of which drive pelvic floor muscle guarding. In patients who already have pelvic floor dysfunction, that guarding is amplified rather than compensated.

"If they are having pelvic floor dysfunction ahead of time, those symptoms can actually worsen," Fosnight said. Early referral to a pelvic floor therapist—framed as prevention rather than treatment of an existing problem—can reduce that amplification before it develops.

"Prevention is a much easier way to help prevent things from happening than treating later on," she said.